Menu

Blog

Feb 18, 2024

Host Cell Protein and Impurity Risk Mitigation in Monoclonal Antibody Therapeutic Manufacturing

Posted by in category: biotech/medical

Biopharmaceutical impurities such as host cell proteins can delay biologics development and production. These elements can have immunogenic effects in patients, forcing scientists to restart process development. Thus, detecting and removing biopharmaceutical impurities is necessary for maintaining drug efficacy and ensuring patient safety.

In this webinar brought to you by Cytiva, Andrew Hamilton and Joe Hirano will discuss how to identify, detect, and measure impurities in biologics manufacturing.

Comments are closed.